{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T17:12:00Z","timestamp":1776273120735,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd003188.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2012,5,16]],"date-time":"2012-05-16T00:00:00Z","timestamp":1337126400000}}],"reference-count":163,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd003188.pub3","type":"journal-article","created":{"date-parts":[[2012,5,10]],"date-time":"2012-05-10T20:00:02Z","timestamp":1336680002000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Bisphosphonates in multiple myeloma: a network meta-analysis"],"prefix":"10.1002","author":[{"given":"Rahul","family":"Mhaskar","sequence":"first","affiliation":[{"name":"University of South Florida; Center for Evidence Based Medicine and Health Outcomes Research; Tampa Florida USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasmina","family":"Redzepovic","sequence":"additional","affiliation":[{"name":"Roche AG; Grenzacherstrasse 124 Basel Switzerland 4070"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"Wheatley","sequence":"additional","affiliation":[{"name":"University of Birmingham; Cancer Research UK Clinical Trials Unit, School of Cancer Sciences; Edgbaston Birmingham UK B15 2TT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Otavio Augusto Camara","family":"Clark","sequence":"additional","affiliation":[{"name":"Scientific Solutions in Healthcare; EVIDENCIAS; Av. Dr. Luis de Tella Campinas San Paolo Brazil 1570"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Branko","family":"Miladinovic","sequence":"additional","affiliation":[{"name":"University of South Florida; Center for Evidence Based Medicine and Health Outcomes Research; Tampa Florida USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Glasmacher","sequence":"additional","affiliation":[{"name":"University of Bonn; Bonn Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ambuj","family":"Kumar","sequence":"additional","affiliation":[{"name":"University of South Florida; Center for Evidence Based Medicine and Health Outcomes Research; Tampa Florida USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Djulbegovic","sequence":"additional","affiliation":[{"name":"USF Health Clinical Research, University of South Florida; USF Clinical Translational Science Institute, Dpts of Medicine, Hematology and Health Outcome Research, USF and H. Lee Moffitt Cancer Center; 12901 Bruce B. Downs Boulevard, CMS 3057 Tampa Florida USA 33612"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,5,16]]},"reference":[{"issue":"10","key":"10.1002\/14651858.CD003188.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","article-title":"Maintenance therapy with thalidomide improves survival in patients with multiple myeloma","volume":"108","author":"Attal","year":"2006","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD003188.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF02698044","article-title":"Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma","volume":"24","author":"Aviles","year":"2007","journal-title":"Medical Oncology (Northwood, London, England)"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1200\/JCO.1991.9.8.1397","article-title":"Effect of daily etidronate on the osteolysis of multiple myeloma","volume":"9","author":"Belch","year":"1991","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0005|cit4","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","article-title":"Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events","volume":"16","author":"Berenson","year":"1998","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0004|cit5","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group","volume":"334","author":"Berenson","year":"1996","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1600-0609.1998.tb01073.x","article-title":"Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma","volume":"61","author":"Abildgaard","year":"1998","journal-title":"European Journal of Hematology"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1046\/j.1365-2141.1998.00695.x","article-title":"Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial","volume":"101","author":"Brincker","year":"1998","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0008|cit8","first-page":"449","article-title":"Treatment of multiple myeloma with etidronate results of a multicentre double-blind study","volume":"2","author":"Daragon","year":"1993","journal-title":"European Journal of Medicine"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0221-8747(82)90013-3","article-title":"Long-term effects of dichloromethylene diphosphonate (CI2MDP) on skeletal lesions in multiple myeloma","volume":"4","author":"Delmas","year":"1982","journal-title":"Metabolic Bone Disease and Related Research"},{"issue":"10","key":"10.1002\/14651858.CD003188.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S1470-2045(10)70198-4","article-title":"Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial","volume":"11","author":"Gimsing","year":"2010","journal-title":"The Lancet Oncology"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/BF01697625","article-title":"Multiple myeloma: effect of daily dichloromethylene bisphosphonate on skeletal Multiple myeloma: effect of daily dichloromethylene bisphosphonate on skeletal complications","volume":"66","author":"Clemens","year":"1993","journal-title":"Annals of Hematology"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0012|cit12","first-page":"439","article-title":"Prospective randomized trial of dichloromethilene bisphosphonate (clodronate) in patients with multiple myeloma","volume":"18","author":"Heim","year":"1995","journal-title":"Onkologie"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0014|cit13","first-page":"379","article-title":"The effect of long-term pamidronate treatment on skeletal morbidity in advanced multiple myeloma","volume":"31","author":"Kraj","year":"2000","journal-title":"Acta Haematologica Polonica"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0013|cit14","first-page":"113","article-title":"Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1: The results of the 12 months of pamidronate therapy","volume":"57 (suppl 1)","author":"Kraj","year":"2000","journal-title":"Acta Poloniae Pharmaceutica"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/0140-6736(92)93075-X","article-title":"Randomized, placebo-controlled multicentre trial of clodronate in multiple myeloma","volume":"340","author":"Lahtinen","year":"1992","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD003188.pub3-BIB0016|cit16","first-page":"377","article-title":"Effects of pamidronate disodium (Bonin) combined with chemotherapy on bone pain in multiple myeloma","volume":"15","author":"Leng","year":"2002","journal-title":"Hang tian yi xue yu yi xue gong cheng = Space Medicine & Medical Engineering"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1046\/j.1365-2141.2001.02851.x","article-title":"Long-term follow-up of a prospective, double-blind, placebo-controlled randomised trial of clodronate in multiple myeloma","volume":"113","author":"McCloskey","year":"2001","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1365-2141.1998.00567.x","article-title":"A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults","volume":"100","author":"McCloskey","year":"1998","journal-title":"British Journal of Haematology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003188.pub3-BIB0019|cit19","first-page":"106a","article-title":"Effects of intravenous ibandronate therapy on skeletal related events (SRE) and survival in patients with advanced multiple myeloma","volume":"92","author":"Fontana","year":"1998","journal-title":"Blood"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1200\/JCO.2002.02.032","article-title":"Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival and bone resorption in patients with advanced multiple myeloma","volume":"20 (9)","author":"Menssen","year":"2002","journal-title":"Journal of Clinical Oncology"},{"issue":"9757","key":"10.1002\/14651858.CD003188.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0022|cit22","first-page":"1","article-title":"Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study","volume":"1","author":"D'arena","year":"2011","journal-title":"Leukemia & Lymphoma"},{"issue":"9","key":"10.1002\/14651858.CD003188.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.3109\/10428190309178778","article-title":"Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: results of a randomized trial","volume":"44","author":"Musto","year":"2003","journal-title":"Leukemia & Lymphoma"},{"issue":"7","key":"10.1002\/14651858.CD003188.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/cncr.23783","article-title":"A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma","volume":"113","author":"Musto","year":"2008","journal-title":"Cancer"},{"issue":"7","key":"10.1002\/14651858.CD003188.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0","article-title":"Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases: a double-blind, randomized dose-response study","volume":"91","author":"Berenson","year":"2001","journal-title":"Cancer"},{"issue":"8","key":"10.1002\/14651858.CD003188.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"issue":"5","key":"10.1002\/14651858.CD003188.pub3-BIB0027|cit27","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cncr.11892","article-title":"Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1034\/j.1600-0609.2000.065005331.x","article-title":"Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma","volume":"65","author":"Terpos","year":"2000","journal-title":"European Journal of Haematology"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1034\/j.1600-0609.2003.02823.x","article-title":"Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6and b2-microglobulin in multiple myeloma","volume":"70","author":"Terpos","year":"2003","journal-title":"European Journal of Haematology"},{"issue":"14","key":"10.1002\/14651858.CD003188.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1200\/JCO.2001.19.14.3434","article-title":"Safety and efficacy of bisphosphonates beyond 24 months in cancer patients","volume":"19","author":"Ali","year":"2001","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD003188.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1182\/blood-2008-06-164228","article-title":"Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease","volume":"112","author":"Barlogie","year":"2008","journal-title":"Blood"},{"issue":"8","key":"10.1002\/14651858.CD003188.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1177\/0091270007301801","article-title":"Renal safety and pharmacokinetics of ibandronate in multiple myeloma patients with or without impaired renal function","volume":"47","author":"Bergner","year":"2007","journal-title":"Journal of Clinical Pharmacology"},{"issue":"6","key":"10.1002\/14651858.CD003188.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/sj.thj.6200311","article-title":"Perspective study on pamidronate in stage I multiple myeloma","volume":"4","author":"Caparrotti","year":"2003","journal-title":"The Hematology Journal"},{"issue":"4","key":"10.1002\/14651858.CD003188.pub3-BIB0035|cit35","first-page":"PI31","article-title":"Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma","volume":"8","author":"Ciepluch","year":"2002","journal-title":"Medical Science Monitor"},{"issue":"10","key":"10.1002\/14651858.CD003188.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2008.19.2146","article-title":"Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates","volume":"27","author":"Fizazi","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"suppl 1","key":"10.1002\/14651858.CD003188.pub3-BIB0037|cit37","first-page":"113","article-title":"Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1. The results of the first 12 months of pamidronate therapy","volume":"57","author":"Kraj","year":"2000","journal-title":"Acta Poloniae Pharmaceutica"},{"issue":"6","key":"10.1002\/14651858.CD003188.pub3-BIB0038|cit38","first-page":"478","article-title":"Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience)","volume":"59","author":"Kraj","year":"2002","journal-title":"Acta Poloniae Pharmaceutica"},{"issue":"1","key":"10.1002\/14651858.CD003188.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1046\/j.1365-2141.2002.03549.x","article-title":"Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect","volume":"118","author":"Mart\u00edn","year":"2002","journal-title":"British Journal of Haematology"},{"issue":"1","key":"10.1002\/14651858.CD003188.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1385\/MO:18:1:79","article-title":"Phase II trial of clarithromycin and pamidronate therapy in myeloma","volume":"18","author":"Morris","year":"2001","journal-title":"Medical Oncology"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1472-6904-8-2","article-title":"Renal safety of zoledronic acid with thalidomide in patients with myeloma: a pharmacokinetic and safety sub-study","volume":"8","author":"Spencer","year":"2008","journal-title":"BMC Clinical Pharmacology"},{"issue":"2","key":"10.1002\/14651858.CD003188.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1089\/jpm.2006.0122","article-title":"Zoledronic acid treatment at home: safety data from an observational prospective trial","volume":"10","author":"Tassinari","year":"2007","journal-title":"Journal of Palliative Medicine"},{"issue":"5","key":"10.1002\/14651858.CD003188.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/leu.2010.62","article-title":"Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease","volume":"24","author":"Terpos","year":"2010","journal-title":"Leukemia"},{"issue":"5","key":"10.1002\/14651858.CD003188.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.0902-4441.2005.t01-1-EJH2520.x","article-title":"First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma","volume":"76","author":"Tosi","year":"2006","journal-title":"European Journal of Haematology"},{"issue":"10","key":"10.1002\/14651858.CD003188.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/ajh.21509","article-title":"An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma","volume":"84","author":"Vij","year":"2009","journal-title":"American Journal of Hematology"},{"issue":"6","key":"10.1002\/14651858.CD003188.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1634\/theoncologist.9-6-687","article-title":"Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy","volume":"9","author":"Vogel","year":"2004","journal-title":"Oncologist"},{"issue":"2","key":"10.1002\/14651858.CD003188.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10006-005-0670-0","article-title":"Bisphosphonate-associated osteonecrosis of the jaw","volume":"10","author":"Abu-Id","year":"2006","journal-title":"Mund Kiefer Gesichtschirurgie"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/jor.1100120518","article-title":"Effect of intermittent administration of pamidronate on the mechanical proprieties of canine cortical and trabecular bone","volume":"12","author":"Acito","year":"1994","journal-title":"Journal of Orthopedic Research"},{"issue":"6","key":"10.1002\/14651858.CD003188.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1097\/01.scs.0000249350.59096.d0","article-title":"New therapeutic protocol in the treatment of avascular necrosis of the jaws","volume":"17","author":"Agrillo","year":"2006","journal-title":"Craniofacial Surgery"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1056\/NEJM199402173300709","article-title":"The treatment of multiple myeloma","volume":"330","author":"Alexanian","year":"1994","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/sj.leu.2400892","article-title":"In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates","volume":"12","author":"Aparicio","year":"1998","journal-title":"Leukemia"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/00002018-200326090-00005","article-title":"Extended safety profile of oral clodronate after long term use in primary breast cancer patients","volume":"26","author":"Atula","year":"2003","journal-title":"Drug Safety"},{"issue":"6","key":"10.1002\/14651858.CD003188.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.2005.04.2465","article-title":"Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors","volume":"24","author":"Badros","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.oraloncology.2005.08.001","article-title":"Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases [Letter]","volume":"42","author":"Bagan","year":"2006","journal-title":"Oral Oncology"},{"issue":"1246","key":"10.1002\/14651858.CD003188.pub3-BIB0055|cit55","first-page":"U2341","article-title":"Jaw osteonecrosis associated with bisphosphonates","volume":"119","author":"Battley","year":"2006","journal-title":"The New Zealand Medical Journal"},{"issue":"4","key":"10.1002\/14651858.CD003188.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0057|cit57","first-page":"195","article-title":"The efficacy of pamidronate disodium in the treatment of osteolytic lesions and bone pain in multiple myeloma","volume":"9","author":"Berenson","year":"1998","journal-title":"Reviews in Contemporary Pharmacotherapy"},{"issue":"1","key":"10.1002\/14651858.CD003188.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/ajh.21912","article-title":"Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid","volume":"86","author":"Berenson","year":"2011","journal-title":"American Journal of Hematology"},{"issue":"4","key":"10.1002\/14651858.CD003188.pub3-BIB0059|cit59","first-page":"315","article-title":"Bisphosphonates: case report of non surgical periodontal therapy and osteochemonecrosis","volume":"26","author":"Braun","year":"2006","journal-title":"International Journal of Periodontics and Restorative Dentistry"},{"issue":"3","key":"10.1002\/14651858.CD003188.pub3-BIB0060|cit60","first-page":"140","article-title":"Avascular jaw osteonecrosis associated with bisphosphonate therapy","volume":"97","author":"Broglia","year":"2006","journal-title":"Recenti Progressi in Medicina (Roma)"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1677\/erc.0.0110207","article-title":"The role of bisphosphonates in breast and prostate cancers","volume":"11","author":"Brown","year":"2004","journal-title":"Endocrine Related Cancer"},{"issue":"6","key":"10.1002\/14651858.CD003188.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"Journal of Clinical Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD003188.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/annonc\/mdl408","article-title":"Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis","volume":"18","author":"Bujanda","year":"2007","journal-title":"Annals of Oncology"},{"issue":"7521","key":"10.1002\/14651858.CD003188.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/bmj.331.7521.897","article-title":"Simultaneous comparison of multiple treatments: combining direct and indirect evidence","volume":"331","author":"Caldwell","year":"2005","journal-title":"BMJ (Clinical research ed.)"},{"issue":"15","key":"10.1002\/14651858.CD003188.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0025-7753(06)72338-7","article-title":"Osteonecrosis of the jaw in patients with multiple myeloma during and after treatment with zoledronic acid","volume":"127","author":"Calvo-Villas","year":"2006","journal-title":"Medicina Clinicia (Barcelona)"},{"issue":"5","key":"10.1002\/14651858.CD003188.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/BF03006939","article-title":"Jaw osteonecrosis associated with use of bisphosphonates and chemotherapy: paradoxical complication of treatment of bone lesions in multiple myeloma patients","volume":"83","author":"Capalbo","year":"2006","journal-title":"International Journal of Hematology"},{"issue":"5","key":"10.1002\/14651858.CD003188.pub3-BIB0067|cit67","first-page":"1096","article-title":"Bisphosphonate-associated mandibular osteonecrosis","volume":"27","author":"Carneiro","year":"2006","journal-title":"American Journal of Neuroradiology"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"413","DOI":"10.5694\/j.1326-5377.2005.tb06761.x","article-title":"Bisphosphonates and avascular necrosis of the jaw: a possible association","volume":"182","author":"Carter","year":"2005","journal-title":"Medical Journal of Australia (Sydney)"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/med:hand\/9780198567875.001.0001","volume-title":"Oxford Handbook of Oncology","author":"Cassidy","year":"2006"},{"issue":"4","key":"10.1002\/14651858.CD003188.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00774-009-0047-9","article-title":"Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid","volume":"27","author":"Cetiner","year":"2009","journal-title":"Journal of Bone and Mineral Metabolism"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM200310233491721","article-title":"Renal failure with the use of zoledronic acid","volume":"349","author":"Chang","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD003188.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.otohns.2006.11.008","article-title":"Bisphosphonates and jaw osteonecrosis: the UAMS experience","volume":"136","author":"Clarke","year":"2007","journal-title":"Otolaryngology--Head and Neck Surgery"},{"issue":"7","key":"10.1002\/14651858.CD003188.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/sj.leu.2404682","article-title":"A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma","volume":"21","author":"Corso","year":"2007","journal-title":"Leukemia"},{"issue":"2","key":"10.1002\/14651858.CD003188.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.joms.2005.12.051","article-title":"Treatment of avascular osteonecrosis of the mandible in cancer patients with a history of bisphosphonate therapy by combining bone resection and autologous platelet-rich plasma: report of 3 cases","volume":"65","author":"Curi","year":"2007","journal-title":"Journal of Oral Maxillofacial Surgery"},{"issue":"4","key":"10.1002\/14651858.CD003188.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.bone.2006.11.023","article-title":"Jaw osteonecrosis related to bisphosphonate therapy: a severe secondary disorder","volume":"40","author":"Dannemann","year":"2007","journal-title":"Bone"},{"issue":"3","key":"10.1002\/14651858.CD003188.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1046\/j.1365-2141.1998.00976.x","article-title":"Anti-myeloma activity of pamidronate in vivo","volume":"103","author":"Dhodapkar","year":"1998","journal-title":"British Journal of Haematology"},{"issue":"7-8","key":"10.1002\/14651858.CD003188.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Statistics in Medicine"},{"issue":"3","key":"10.1002\/14651858.CD003188.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.tripleo.2006.09.022","article-title":"Bisphosphonate-associated osteonecrosis of the jaws: a therapeutic dilemma","volume":"103","author":"Diego","year":"2007","journal-title":"Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics"},{"issue":"7","key":"10.1002\/14651858.CD003188.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ijom.2006.02.022","article-title":"Bisphosphonate-induced avascular osteonecrosis of the jaws: a clinical report of 11 cases","volume":"35","author":"Dimitrakopoulos","year":"2006","journal-title":"International Journal of Oral and Maxillofacillary Surgery"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0081|cit81","first-page":"968","article-title":"Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid","volume":"91","author":"Dimopoulos","year":"2006","journal-title":"Haematologica"},{"issue":"4","key":"10.1002\/14651858.CD003188.pub3-BIB0082|cit82","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003188","article-title":"Bisphosphonates in multiple myeloma","author":"Djulbegovic","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD003188.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clinic Proceedings"},{"issue":"2","key":"10.1002\/14651858.CD003188.pub3-BIB0084|cit84","first-page":"235","article-title":"Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates","volume":"296","author":"Dunford","year":"2001","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0085|cit85","doi-asserted-by":"crossref","unstructured":"Durie BG Katz M Crowley J Osteonecrosis of the jaw and bisphosphonates The New England Journal of Medicine 2005 99-102; discussion 99-102","DOI":"10.1056\/NEJM200507073530120"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0086|cit86","doi-asserted-by":"crossref","DOI":"10.1002\/9780470693926","volume-title":"Systematic Reviews in Health Care: Meta-analysis in Context. 2nd edition","author":"Egger","year":"2001"},{"issue":"6","key":"10.1002\/14651858.CD003188.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1365-2257.2006.00841.x","article-title":"Osteomylelitis and necrosis of the jaw in patients treated with bisphosphonates: a comparative study focused on multiple myeloma","volume":"28","author":"Elad","year":"2006","journal-title":"Clinical and Laboratory Haematology"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0088|cit88","first-page":"750","article-title":"Osteonecrosis of the maxilla and mandible in patients treated with bisphosphonates: a retrospective study [Abstract]","volume":"22","author":"Estilo","year":"2004","journal-title":"Proceedings of American Society of Clinical Oncology"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1600-051X.2005.00842.x","article-title":"Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment","volume":"32","author":"Ficarra","year":"2005","journal-title":"Journal of Clinical Periodontology"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/BF01625440","article-title":"Differential action of pamidronate on trabecular and cortical bone in women with involutional osteoporosis","volume":"1","author":"Fromm","year":"1991","journal-title":"Osteoporosis International"},{"issue":"11","key":"10.1002\/14651858.CD003188.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"Abstract 5086","DOI":"10.1182\/blood.V108.11.5086.5086","article-title":"Osteonecrosis of the jaw in multiple myeloma patients: experience of two hospitals","volume":"108","author":"Garcia-Garay","year":"2006","journal-title":"Blood"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"549","DOI":"10.5694\/j.1326-5377.2005.tb07172.x","article-title":"Bisphosphonate-induced osteonecrosis of the jaw requires early detection and intervention [Letter]","volume":"183","author":"Gibbs","year":"2005","journal-title":"The Medical Journal of Australia"},{"issue":"26","key":"10.1002\/14651858.CD003188.pub3-BIB0093|cit93","first-page":"1-134, iii-iv","article-title":"Indirect comparisons of competing interventions","volume":"9","author":"Glenny","year":"2005","journal-title":"Health Technology Assessment (Winchester, England)"},{"issue":"3","key":"10.1002\/14651858.CD003188.pub3-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1600-0714.2006.00391.x","article-title":"Osteonecrosis of the jaws in patients treated with bisphosphonates: histomorphologic analysis in comparison with infected osteoradionecrosis","volume":"35","author":"Hansen","year":"2006","journal-title":"Journal of Oral Pathology & Medicine"},{"issue":"1","key":"10.1002\/14651858.CD003188.pub3-BIB0095|cit95","first-page":"4","article-title":"Association of osteonecrosis of the jaws and bisphosphonate pharmacotherapy: dental implications","volume":"102","author":"Hay","year":"2006","journal-title":"The New Zealand Dental Journal"},{"issue":"8","key":"10.1002\/14651858.CD003188.pub3-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.joms.2007.03.021","article-title":"Severe spontaneous cases of bisphosphonate-related osteonecrosis of the jaws","volume":"65","author":"Herbozo","year":"2007","journal-title":"Journal of Oral and Maxillofacial Surgery"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0097|cit97","doi-asserted-by":"crossref","unstructured":"Higgins JP Whitehead A Borrowing strength from external trials in a meta-analysis Statistics in Medicine 1996 2733 49 10.1002\/(SICI)1097-0258(19961230)15:24<2733::AID-SIM562>3.0.CO;2-0","DOI":"10.1002\/(SICI)1097-0258(19961230)15:24<2733::AID-SIM562>3.0.CO;2-0"},{"issue":"7414","key":"10.1002\/14651858.CD003188.pub3-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ (Clinical research ed.)"},{"issue":"11","key":"10.1002\/14651858.CD003188.pub3-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1002\/sim.1752","article-title":"Controlling the risk of spurious findings from meta-regression","volume":"23","author":"Higgins","year":"2004","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"8528a","DOI":"10.1200\/jco.2006.24.18_suppl.8528","article-title":"Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy","volume":"24","author":"Hoff","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD003188.pub3-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.amjoto.2008.07.014","article-title":"Clinical experiences with bisphosphonate-associated osteonecrosis of the jaws: analysis of 21 cases","volume":"30","author":"Junquera","year":"2009","journal-title":"American Journal of Otolaryngology"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/bmj.323.7303.42","article-title":"Assessing the quality of controlled clinical trials","volume":"323","author":"J\u00fcni","year":"2001","journal-title":"BMJ"},{"issue":"8","key":"10.1002\/14651858.CD003188.pub3-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.4065\/81.8.1100","article-title":"Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy","volume":"81","author":"Kademani","year":"2006","journal-title":"Mayo Clinic Proceedings"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1097\/01.don.0000186481.96169.cd","article-title":"Endodontic implications of bisphosphonate-associated osteonecrosis of the jaws: a report of three cases","volume":"31","author":"Katz","year":"2005","journal-title":"Journal of Endodontics"},{"issue":"3","key":"10.1002\/14651858.CD003188.pub3-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1210\/jc.2006-2036","article-title":"Possible association between diabetes and bisphosphonate-related jaw osteonecrosis","volume":"92","author":"Khamaisi","year":"2007","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"issue":"5","key":"10.1002\/14651858.CD003188.pub3-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"602","DOI":"10.14219\/jada.archive.2007.0230","article-title":"Bisphosphonate-related osteonecrosis of the jaws: a report of three cases demonstrating variability in outcomes and morbidity","volume":"138","author":"Kumar","year":"2007","journal-title":"Journal of the American Dental Association"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"Abstract 4933","DOI":"10.1182\/blood.V104.11.4933.4933","article-title":"Osteonecrosis of the jaw in myeloma patients receiving pamidronate or zoledronate","volume":"104","author":"Kut","year":"2004","journal-title":"Blood"},{"issue":"15","key":"10.1002\/14651858.CD003188.pub3-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1002\/sim.2112","article-title":"How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS","volume":"24","author":"Lambert","year":"2005","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJM198806303182605","article-title":"An assessment of clinically useful measures of the consequences of treatment","volume":"318","author":"Laupacis","year":"1988","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD003188.pub3-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.joms.2008.11.015","article-title":"Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients","volume":"67","author":"Lazarovici","year":"2009","journal-title":"Journal of Oral and Maxillofacial Surgery"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jcms.2005.07.007","article-title":"Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates?","volume":"33","author":"Lenz","year":"2005","journal-title":"Jornal of Craniomaxillofacillary Surgery"},{"issue":"10","key":"10.1002\/14651858.CD003188.pub3-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"62","author":"Liberati","year":"2009","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0113|cit113","doi-asserted-by":"crossref","unstructured":"Lu G Ades AE Combination of direct and indirect evidence in mixed treatment comparisons Statistics in Medicine 2004 3105 24 10.1002\/sim.1875","DOI":"10.1002\/sim.1875"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/BF01622190","article-title":"Pamidronate: an unrecognized problem in gastrointestinal tolerability","volume":"4","author":"Lufkin","year":"1994","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.amjmed.2004.04.015","article-title":"Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: a new clinical entity","volume":"117","author":"Lugassy","year":"2004","journal-title":"American Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD003188.pub3-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.amjoto.2006.08.004","article-title":"Osteonecrosis of the jaws due to bisphosphonate use: a review of 60 cases and treatment proposals","volume":"28","author":"Magopoulos","year":"2007","journal-title":"American Journal of Otolaryngology"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0117|cit117","first-page":"44","article-title":"Adverse oral sequelae to bisphosphonate administration","volume":"87","author":"Marunick","year":"2005","journal-title":"Journal of Michigan Dental Association"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0118|cit118","doi-asserted-by":"crossref","unstructured":"Marx RE Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic Journal of Oral and Maxillofacial Surgery 2003 1115 7","DOI":"10.1016\/S0278-2391(03)00720-1"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.joms.2005.07.010","article-title":"Bisphosphonate-induced exposed bone (osteonecrosis\/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment","volume":"63","author":"Marx","year":"2005","journal-title":"Journal of Oral and Maxillofacial Surgery"},{"issue":"3","key":"10.1002\/14651858.CD003188.pub3-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.joms.2006.10.061","article-title":"Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia","volume":"65","author":"Mavrokokki","year":"2007","journal-title":"Journal of Oral and Maxillofacial Surgery"},{"issue":"12","key":"10.1002\/14651858.CD003188.pub3-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.14219\/jada.archive.2005.0110","article-title":"Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition","volume":"136","author":"Melo","year":"2005","journal-title":"Jornal of the American Dental Association"},{"issue":"2","key":"10.1002\/14651858.CD003188.pub3-BIB0122|cit122","first-page":"109","article-title":"Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases","volume":"77","author":"Merigo","year":"2006","journal-title":"Acta Bio-medica: Atenei Parmensis"},{"issue":"3","key":"10.1002\/14651858.CD003188.pub3-BIB0123|cit123","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003188.pub2","article-title":"Bisphosphonates in multiple myeloma","author":"Mhaskar","year":"2010","journal-title":"Cochrane Database of Systematic Reviews (Online)"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/cncr.21130","article-title":"Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy","volume":"104","author":"Migliorati","year":"2005","journal-title":"Cancer"},{"issue":"1","key":"10.1002\/14651858.CD003188.pub3-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1600-0609.2007.00872.x","article-title":"Oral sodium clodronate induced osteonecrosis of the jaw in a patient with myeloma","volume":"79","author":"Montazeri","year":"2007","journal-title":"European Journal of Haematology"},{"issue":"1","key":"10.1002\/14651858.CD003188.pub3-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/01.mlg.0000240885.64568.9e","article-title":"Osteonecrosis of the jaw associated with bisphosphonate use: Presentation of seven cases and literature review","volume":"117","author":"Mortensen","year":"2007","journal-title":"Laryngoscope"},{"issue":"3","key":"10.1002\/14651858.CD003188.pub3-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"232","DOI":"10.4158\/EP.13.3.232","article-title":"Bisphosphonates and osteonecrosis of the jaw: a retrospective study","volume":"13","author":"Murad","year":"2007","journal-title":"Endocrine Practice"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0128|cit128","first-page":"76","article-title":"Osteonecrosis of the jaws and bisphosphonates: report of three cases","volume":"11","author":"Pastor-Zuazaga","year":"2006","journal-title":"Medicina Oral, Patolog\u00eda Oral y Cirug\u00eda Bucal"},{"issue":"6","key":"10.1002\/14651858.CD003188.pub3-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3174\/ajnr.A0518","article-title":"Imaging findings of bisphosphonate-associated osteonecrosis of the jaws","volume":"28","author":"Phal","year":"2007","journal-title":"American Journal of Neuroradiology"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1601-0825.2005.01130.x","article-title":"Oral avascular bone necrosis associated with chemotherapy and bisphosphonate therapy","volume":"11","author":"Pires","year":"2005","journal-title":"Oral Diseases"},{"issue":"1","key":"10.1002\/14651858.CD003188.pub3-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1365-2141.2005.05833.x","article-title":"Bisphosphonate-associated osteonecrosis of the auditory canal","volume":"132","author":"Polizzotto","year":"2006","journal-title":"British Journal of Haematology"},{"issue":"1","key":"10.1002\/14651858.CD003188.pub3-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1080\/10428190600977690","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients","volume":"48","author":"Pozzi","year":"2007","journal-title":"Leukemia & Lymphoma"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"417","DOI":"10.5694\/j.1326-5377.2005.tb06762.x","article-title":"Bisphosphonates and osteonecrosis of the jaw","volume":"182","author":"Purcell","year":"2005","journal-title":"Medical Journal of Australia"},{"issue":"9757","key":"10.1002\/14651858.CD003188.pub3-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/S0140-6736(10)62178-2","article-title":"Zoledronic acid in myeloma: MRC Myeloma IX","volume":"376","author":"Rajkumar","year":"2010","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0135|cit135","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2011"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases","volume":"62","author":"Ruggiero","year":"2004","journal-title":"Journal of Oral and Maxillofacillary Surgery"},{"issue":"2","key":"10.1002\/14651858.CD003188.pub3-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4B","key":"10.1002\/14651858.CD003188.pub3-BIB0138|cit138","first-page":"3111","article-title":"Bisphosphonates and oral cavity avascular bone necrosis: a review of twelve cases","volume":"26","author":"Salesi","year":"2006","journal-title":"Anticancer Research"},{"issue":"2","key":"10.1002\/14651858.CD003188.pub3-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/lary.20076","article-title":"Bisphosphonate-related osteonecrosis of the jaw and its associated risk factors: a Belgian case series","volume":"119","author":"Saussez","year":"2009","journal-title":"The Laryngoscope"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias, dimension of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD003188.pub3-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/1098-2272(200009)19:2<127::AID-GEPI2>3.0.CO;2-S","article-title":"Variance components analysis for pedigree-based censored survival data using generalized linear mixed models (GLMMs) and Gibbs sampling in BUGS","volume":"19","author":"Scurrah","year":"2000","journal-title":"Genetic Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD003188.pub3-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"61","DOI":"10.14219\/jada.archive.2009.0019","article-title":"Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: an institutional inquiry","volume":"140","author":"Sedghizadeh","year":"2009","journal-title":"Journal of the American Dental Association"},{"issue":"3","key":"10.1002\/14651858.CD003188.pub3-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.joms.2006.10.043","article-title":"Severe osteomyelitis of the mandible associated with the use of non-nitrogen-containing bisphosphonate (disodium clodronate): report of a case","volume":"65","author":"Senel","year":"2007","journal-title":"Journal of Oral and Maxillofacillary Surgery"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1046\/j.1365-2141.1997.2713086.x","article-title":"Bisphosphonates induce apoptosis in human myeloma cells: a novel anti-tumour activity","volume":"98","author":"Shipman","year":"1997","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0145|cit145","first-page":"968","article-title":"Bisphosphonates, dental care and osteonecrosis of the jaws","volume":"122","author":"Sitters","year":"2005","journal-title":"Texas Dental Journal"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0146|cit146","unstructured":"StataCorp LP STATA 2008"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/9780470693926.ch11","article-title":"Investigating and dealing with publication and other biases","volume-title":"Systematic Reviews in Health Care: Meta-analysis in Context. 2nd edition","author":"Sterne","year":"2001"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/annonc\/mdj105","article-title":"Management of the adverse effects associated with intravenous bisphosphonates","volume":"17","author":"Tanvetyanon","year":"2006","journal-title":"Annals of Oncology"},{"issue":"23","key":"10.1002\/14651858.CD003188.pub3-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1002\/(SICI)1097-0258(19971215)16:23<2741::AID-SIM703>3.0.CO;2-0","article-title":"Investigating underlying risk as a source of heterogeneity in meta-analysis","volume":"16","author":"Thompson","year":"1997","journal-title":"Statistics in Medicine"},{"issue":"11","key":"10.1002\/14651858.CD003188.pub3-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/sim.1187","article-title":"How should meta-regression analyses be undertaken and interpreted?","volume":"21","author":"Thompson","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"12","key":"10.1002\/14651858.CD003188.pub3-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1182\/blood-2006-07-033571","article-title":"Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone","volume":"108","author":"Tosi","year":"2006","journal-title":"Blood"},{"issue":"22","key":"10.1002\/14651858.CD003188.pub3-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1056\/NEJMicm055784","article-title":"Images in clinical medicine. Bisphosphonate-associated osteonecrosis of the jaw","volume":"355","author":"Treister","year":"2006","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0154|cit154","article-title":"Multiple myeloma and other plasma cell disorders","volume-title":"Hematology: Basic Principles and Practice","author":"Tricot","year":"2000"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/JCO.1993.11.3.491","article-title":"Palliative pamidronate treatment in patients with bone metastases from breast cancer","volume":"11","author":"Holten-Verzantvoort","year":"1993","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1365-2141.2005.05382.x","article-title":"Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma","volume":"28","author":"Vannucchi","year":"2005","journal-title":"British Journal of Haematology"},{"issue":"2","key":"10.1002\/14651858.CD003188.pub3-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00520-006-0120-z","article-title":"Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis","volume":"15","author":"Walter","year":"2007","journal-title":"Support Care Cancer"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0158|cit158","first-page":"3","volume-title":"Indirect Evidence: Indirect Treatment Comparisons in Meta-analysis","author":"Wells","year":"2009"},{"issue":"2","key":"10.1002\/14651858.CD003188.pub3-BIB0159|cit159","article-title":"Bisphosphonates for the relief of pain secondary to bone metastases","author":"Wong","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"15-16","key":"10.1002\/14651858.CD003188.pub3-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00508-006-0644-8","article-title":"Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients","volume":"118","author":"Wutzl","year":"2006","journal-title":"Wiener Klinische Wochenschrift"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0161|cit161","first-page":"36","article-title":"Bisphosphonate-related osteonecrosis of the jaws","volume":"27","author":"Yeo","year":"2005","journal-title":"Singapore Dental Journal"},{"key":"10.1002\/14651858.CD003188.pub3-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/ajh.20481","article-title":"Osteonecrosis of the jaw associated with pamidronate therapy","volume":"81","author":"Zarychanski","year":"2006","journal-title":"American Journal of Hematology"},{"issue":"6","key":"10.1002\/14651858.CD003188.pub3-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1365-2141.2006.06230.x","article-title":"Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients","volume":"134","author":"Zervas","year":"2006","journal-title":"British Journal of Haematology"}],"updated-by":[{"DOI":"10.1002\/14651858.cd003188.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,12,18]],"date-time":"2017-12-18T00:00:00Z","timestamp":1513555200000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD003188.pub3\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T21:17:12Z","timestamp":1628543832000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD003188.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Haematological Malignancies Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2012,5,16]]},"references-count":163,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003188.pub3","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD003188.pub4","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,16]]}}}